MTCR - MTCR STOCK NEWS

Metacrine, Inc. (Nasdaq: MTCR) is set to present at the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, at 4:20 p.m. ET. CEO Preston Klassen will lead the discussion, which will be broadcast live on the company's investor website. Metacrine focuses on developing therapies for liver and gastrointestinal diseases, utilizing a proprietary farnesoid X receptor platform. Its product candidates, MET409 and MET642, are in clinical trials for non-alcoholic steatohepatitis (NASH), with MET409 also targeting type 2 diabetes.

Metacrine announced promising results from a 12-week Phase 1b study of MET409, a farnesoid X receptor (FXR) agonist, published in the Journal of Hepatology. The trial showed a 38% mean relative liver fat reduction with a 16% pruritus rate, maintaining tolerability. The study supports MET409's potential as a treatment for non-alcoholic steatohepatitis (NASH), a serious liver disease with no approved therapies. The results position MET409 favorably for both monotherapy and combination therapy with anti-diabetic medications, addressing significant unmet medical needs.

Metacrine (Nasdaq: MTCR) announced FDA Fast Track designation for MET642, its second FXR agonist aimed at treating non-alcoholic steatohepatitis (NASH). This follows favorable Phase 1 results, where MET642 showed safety and robust FXR engagement without adverse effects. The designation allows for expedited development and review, potentially enabling rolling submissions for its New Drug Application. Metacrine plans to initiate a Phase 2a trial for MET642 in patients with NASH in the first half of 2021. The company continues to advance its FXR platform addressing significant unmet needs.

Metacrine, Inc. (Nasdaq: MTCR) has initiated a Phase 2a clinical trial for MET409, a treatment for patients with both type 2 diabetes and nonalcoholic steatohepatitis (NASH). The trial will evaluate the combination of MET409 with empagliflozin (Jardiance^®), a sodium-glucose cotransport-2 inhibitor. The study aims to assess the safety, tolerability, and liver fat reduction efficacy over 12 weeks. Previous trials indicated MET409 achieved a 38% mean liver fat reduction. Topline data is expected in 2022, targeting a significant patient population with unmet needs.

Metacrine, Inc. (Nasdaq: MTCR) announced positive preliminary results from its Phase 1 trial of MET642, a drug targeting non-alcoholic steatohepatitis (NASH). The trial demonstrated MET642's safety, with no serious adverse events, and a sustained pharmacokinetic profile. The drug maintained robust FXR target engagement, showing up to a 95% decrease in C4 biomarker levels. Metacrine plans to advance MET642 into a Phase 2a trial in NASH patients with dosing scheduled for 1H21, intending to investigate 3 mg and 6 mg doses for potential liver fat reduction.

Metacrine, Inc. (Nasdaq: MTCR) announced its participation in upcoming investor conferences in December. CEO Preston Klassen will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, where Metacrine will engage in 1x1 meetings on December 2. Additionally, the company will be part of the Evercore ISI 3rd Annual HealthCONx on December 3 at 3:55 p.m. ET, also participating in 1x1 investor meetings that day. Webcasts of the presentations will be accessible on Metacrine's website, archived for 60 days.

Metacrine, Inc. (MTCR) has reported significant advancements in its FXR platform, primarily involving MET409 for treating NASH. The company successfully completed an $85 million IPO, enhancing its financial position. Key data from MET409 will be presented at AASLD's conference, reinforcing its potential as a leading therapy. Recent Phase 1b trials demonstrated MET409's effectiveness in reducing liver fat with an acceptable safety profile. The FDA has granted MET409 Fast Track designation, facilitating its development. Cash reserves stand at $109.2 million as of Sept 30, 2020.

Metacrine, Inc. (Nasdaq: MTCR) has announced promising new data from its MET409 clinical trial for non-alcoholic steatohepatitis (NASH). The findings will be presented at the AASLD The Liver Meeting Digital Experience on November 13-16, 2020. MET409 showed robust FXR activation, indicating strong therapeutic potential, with significant liver fat reductions observed as early as week 4. Notably, reduction in liver fat content after 4 weeks strongly predicts 12-week outcomes. These results position MET409 as a leading candidate for NASH treatment amidst the lack of approved therapies.

Metacrine, a clinical-stage biopharmaceutical company, has priced its initial public offering (IPO) at $13.00 per share, offering 6,540,000 shares to raise approximately $85 million before expenses. The IPO will enable trading under the ticker symbol MTCR on the Nasdaq Global Market, with trading expected to commence on September 16, 2020. The underwriters have a 30-day option to purchase an additional 981,000 shares. The offering is set to close on September 18, 2020, subject to customary closing conditions.